Company profile
SOLIGENIX, INC.
NASDAQ:SNGXBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| DUSQUETIDE | phase3 | — | 2 | no active trials |
| Hypericin | phase3 | — | 1 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02013050 | phase2 | completed | 2013-12-01 | 2015-12-01 | Soligenix | A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer |
| NCT01073384 | phase1_2 | completed | 2009-12-01 | 2012-01-01 | Soligenix | A Dose Ranging Study of Delayed Release Beclomethasone for Prevention of Acute Enteritis in Patients With Rectal Cancer |
| NCT06470451 | phase3 | terminated | 2025-01-07 | 2026-05-22 | Soligenix | Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL |
| NCT03237325 | phase3 | completed | 2017-12-04 | 2020-06-24 | Soligenix | DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer |
| NCT06386744 | phase2 | completed | 2024-11-18 | 2025-05-23 | Soligenix | Dusquetide for the Treatment of Behcet's Disease |
FDA applications (0)
No records yet.